List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1072686/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human Monocyte-Derived Macrophages (MDM): Model 2. Methods in Molecular Biology, 2022, 2407, 97-101.	0.9	0
2	Jurkat-Derived (J-Lat, J1.1, and Jurkat E4) and CEM-Derived T Cell Lines (8E5 and ACH-2) as Models of Reversible Proviral Latency. Methods in Molecular Biology, 2022, 2407, 3-15.	0.9	1
3	U1 and OM10.1. Myeloid Cell Lines as Surrogate Models of Reversible Proviral Latency. Methods in Molecular Biology, 2022, 2407, 17-28.	0.9	1
4	A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method. Viruses, 2022, 14, 313.	3.3	10
5	Host Restriction Factors Modulating HIV Latency and Replication in Macrophages. International Journal of Molecular Sciences, 2022, 23, 3021.	4.1	9
6	TRIM22. A Multitasking Antiviral Factor. Cells, 2021, 10, 1864.	4.1	21
7	HLA-E–restricted CD8+ T Lymphocytes Efficiently Control Mycobacterium tuberculosis and HIV-1 Coinfection. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 430-439.	2.9	13
8	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA. Journal of Virus Eradication, 2020, 6, 85-95.	0.5	0
9	Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines. Virus Research, 2019, 269, 197631.	2.2	10
10	The ATP/P2X7 axis in human immunodeficiency virus infection of macrophages. Current Opinion in Pharmacology, 2019, 47, 46-52.	3.5	9
11	The interferon-stimulated gene TRIM22 : A double-edged sword in HIV-1 infection. Cytokine and Growth Factor Reviews, 2018, 40, 40-47.	7.2	26
12	Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12–15 December 2017, Miami, FL, USA. Journal of Virus Eradication, 2018, 4, 132-142.	0.5	0
13	P-D2 TRIM22 binds to CIITA and sequesters it into nuclear bodies containing TRIM19/PML and Cyclin T1: Implications for HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 59-59.	2.1	1
14	D-105 Reversible HIV-1 Latency Induced in Primary Human Monocyte-Derived Macrophages by Repeated M1 Polarization. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 40-40.	2.1	1
15	Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization. Scientific Reports, 2018, 8, 14249.	3.3	23
16	Highlights from the 8 International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. Journal of Virus Eradication, 2018, 4, 132-142.	0.5	1
17	5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract. Antiviral Research, 2017, 142, 16-20.	4.1	6
18	Human Endometrial Stromal Cells Are Highly Permissive To Productive Infection by Zika Virus. Scientific Reports, 2017, 7, 44286.	3.3	50

#	Article	IF	CITATIONS
19	Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control. Scientific Reports, 2017, 7, 42470.	3.3	21
20	Chronically infected T-cell lines become handy for a novel assay measuring the reservoir of replication-competent HIV-1. Aids, 2017, 31, 2555-2556.	2.2	1
21	HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nature Communications, 2017, 8, 498.	12.8	78
22	Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. Frontiers in Immunology, 2017, 8, 564.	4.8	16
23	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8–11 December 2015, Miami, Florida, USA. Journal of Virus Eradication, 2016, 2, 57-65.	0.5	7
24	681. HIV-1 Mediated Insertional Activation of STAT5B and BACH2 Promotes the Formation of a Viral Reservoir in T Regulatory Cells. Molecular Therapy, 2016, 24, S269-S270.	8.2	0
25	Plastic restriction of HIV-1 replication in human macrophages derived from M1/M2 polarized monocytes. Journal of Leukocyte Biology, 2016, 100, 1147-1153.	3.3	15
26	The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. Journal of Translational Medicine, 2016, 14, 94.	4.4	20
27	Immuno-Pharmacological Targeting of Virus-Containing Compartments in HIV-1-Infected Macrophages. Trends in Microbiology, 2016, 24, 558-567.	7.7	15
28	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. Journal of Virus Eradication, 2016, 2, 57-65.	0.5	3
29	Zika Virus: a re-emerging pathogen with rapidly evolving public health implications. New Microbiologica, 2016, 39, 86-90.	0.1	6
30	CD14+ macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide. BMC Infectious Diseases, 2015, 15, 430.	2.9	16
31	Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3265-73.	7.1	61
32	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	7.1	154
33	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. Journal of Translational Medicine, 2014, 12, 335.	4.4	13
34	Novel factors interfering with human immunodeficiency virusâ€ŧype 1 replication <i>in vivo</i> and <i>in vitro</i> . Tissue Antigens, 2013, 81, 61-71.	1.0	18
35	Cell-to-cell vs. cell-free HIV-1 transmission from macrophages to CD4+ T lymphocytes. Aids, 2013, 27, 2307-2308.	2.2	4
36	Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. Aids, 2013, 27, 2335-2344.	2.2	17

#	Article	IF	CITATIONS
37	Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. Mucosal Immunology, 2013, 6, 1081-1090.	6.0	71
38	Impaired CD4+ T-Cell Restoration in the Small Versus Large Intestine of HIV-1–Positive South Africans Receiving Combination Antiretroviral Therapy. Journal of Infectious Diseases, 2013, 208, 1113-1122.	4.0	19
39	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. PLoS Pathogens, 2013, 9, e1003515.	4.7	109
40	Macrophage Polarization at the Crossroad Between HIV-1 Infection and Cancer Development. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1145-1152.	2.4	48
41	Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin mediates HIV-1 infection of and transmission by M2a-polarized macrophages in vitro. Aids, 2013, 27, 707-716.	2.2	19
42	M1 polarization of human monocyte-derived macrophages restricts pre and postintegration steps of HIV-1 replication. Aids, 2013, 27, 1847-1856.	2.2	54
43	The Puzzling Role of CXCR4 in Human Immunodeficiency Virus Infection. Theranostics, 2013, 3, 18-25.	10.0	23
44	HIV-1 Infected Lymphoid Organs Upregulate Expression and Release of the Cleaved Form of uPAR That Modulates Chemotaxis and Virus Expression. PLoS ONE, 2013, 8, e70606.	2.5	18
45	Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. International Journal of Molecular Sciences, 2012, 13, 5674-5699.	4.1	22
46	Single-Nucleotide Polymorphism–Defined Class I and Class III Major Histocompatibility Complex Genetic Subregions Contribute to Natural Long-term Nonprogression in HIV Infection. Journal of Infectious Diseases, 2012, 205, 718-724.	4.0	28
47	Passport control for foreign integrated DNAs. Mobile Genetic Elements, 2012, 2, 233-238.	1.8	2
48	Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2284-93.	7.1	39
49	HIV-1 envelope-dependent restriction of CXCR4-using viruses in child but not adult untransformed CD4+ T-lymphocyte lines. Blood, 2012, 119, 2013-2023.	1.4	6
50	Towards an HIV cure: a global scientific strategy. Nature Reviews Immunology, 2012, 12, 607-614.	22.7	485
51	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. Journal of Immunological Methods, 2012, 375, 46-56.	1.4	11
52	A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity. PLoS ONE, 2012, 7, e36833.	2.5	67
53	Negative Regulation of HIV-1 Transcription by a Heterodimeric NF-κB1/p50 and C-Terminally Truncated STAT5 Complex. Journal of Molecular Biology, 2011, 410, 933-943.	4.2	17
54	Macrophage Polarization in Health and Disease. Scientific World Journal, The, 2011, 11, 2391-2402.	2.1	237

#	Article	IF	CITATIONS
55	Urokinase Plasminogen Activator Inhibits HIV Virion Release from Macrophage-Differentiated Chronically Infected Cells via Activation of RhoA and PKCε. PLoS ONE, 2011, 6, e23674.	2.5	14
56	Old and new plasma biomarkers in HIV-1-infected African–American women. Aids, 2011, 25, 1921-1923.	2.2	1
57	Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors. Future Virology, 2011, 6, 521-533.	1.8	1
58	Introducing the issue on "Differential use of CCR5 versus CXCR4 by HIV-1. Pathogenic, Translational and Clinical Open Questions― Journal of Translational Medicine, 2011, 9, 11.	4.4	2
59	TRIM22 Inhibits HIV-1 Transcription Independently of Its E3 Ubiquitin Ligase Activity, Tat, and NF-κB-Responsive Long Terminal Repeat Elements. Journal of Virology, 2011, 85, 5183-5196.	3.4	87
60	Major Histocompatibility Complex Class II Transactivator CIITA Is a Viral Restriction Factor That Targets Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibits Viral Replication. Journal of Virology, 2011, 85, 10719-10729.	3.4	31
61	HIV and Cytokines. , 2011, , 139-153.		0
62	Asymmetric HIV-1 co-receptor use and replication in CD4+ T lymphocytes. Journal of Translational Medicine, 2010, 9, S8.	4.4	13
63	Nef-specific CD45RA+ CD8+ T cells secreting MIP-1Î ² but not IFN-Î ³ are associated with nonprogressive HIV-1 infection. AIDS Research and Therapy, 2010, 7, 20.	1.7	8
64	Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukinâ€2. HIV Medicine, 2010, 11, 349-352.	2.2	1
65	Persistent Microbial Translocation and Immune Activation in HIVâ€1–Infected South Africans Receiving Combination Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 202, 723-733.	4.0	178
66	Characterization of HIV Type 1 Genetic Diversity Among South African Participants Enrolled in the AIDS Vaccine Integrated Project (AVIP) Study. AIDS Research and Human Retroviruses, 2010, 26, 705-709.	1.1	9
67	The rise andÂfall ofÂintermittent interleukin-2 therapy inÂHIV infection. European Cytokine Network, 2010, 21, 197-201.	2.0	5
68	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	12.6	2
69	Post-entry events of efficient R5 vs. inefficient X4 HIV-1 replication in primary CD4+T lymphocytes, a transcriptome analysis. Retrovirology, 2009, 6, 119.	2.0	2
70	Naturally C-Terminally truncated STAT5 (STAT5Δ): a novel negative controller of HIV-1 transcription and expression. Retrovirology, 2009, 6, .	2.0	0
71	M1 and M2a Polarization of Human Monocyte-Derived Macrophages Inhibits HIV-1 Replication by Distinct Mechanisms. Journal of Immunology, 2009, 182, 6237-6246.	0.8	172
72	Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines. Aids, 2009, 23, 567-577.	2.2	22

#	Article	IF	CITATIONS
73	Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells. Blood, 2009, 113, 1699-1709.	1.4	13
74	Macrophage polarization and HIV-1 infection. Journal of Leukocyte Biology, 2009, 87, 599-608.	3.3	139
75	New players in cytokine control of HIV infection. Current HIV/AIDS Reports, 2008, 5, 27-32.	3.1	43
76	The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. AIDS Research and Therapy, 2008, 5, 22.	1.7	19
77	Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy. Clinical and Experimental Immunology, 2008, 152, 252-257.	2.6	15
78	Biological and Technical Variables Affecting Immunoassay Recovery of Cytokines from Human Serum and Simulated Vaginal Fluid: A Multicenter Study. Analytical Chemistry, 2008, 80, 4741-4751.	6.5	161
79	Inhibition of Herpes Simplex Virus Types 1 and 2 In Vitro Infection by Sulfated Derivatives of Escherichia coli K5 Polysaccharide. Antimicrobial Agents and Chemotherapy, 2008, 52, 3078-3084.	3.2	25
80	Persistent Replication of Severe Acute Respiratory Syndrome Coronavirus in Human Tubular Kidney Cells Selects for Adaptive Mutations in the Membrane Protein. Journal of Virology, 2008, 82, 5137-5144.	3.4	50
81	HIV Latency and Reactivation: The Early Years. , 2008, , 279-287.		0
82	Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. Journal of Leukocyte Biology, 2007, 82, 1212-1220.	3.3	16
83	Busting a gut understanding HIV pathogenesis in lymphoid tissue. Future HIV Therapy, 2007, 1, 247-250.	0.4	0
84	Postgenomic up-regulation of CCL3L1 expression in HTLV-2–infected persons curtails HIV-1 replication. Blood, 2007, 109, 1850-1856.	1.4	34
85	Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. Blood, 2007, 109, 5380-5389.	1.4	36
86	Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: Possible protective effect of infecting HCV genotype on HIV disease progression. Journal of Clinical Virology, 2007, 39, 82-86.	3.1	13
87	Heterogeneity of Signal Transducer and Activator of Transcription Binding Sites in the Long-Terminal Repeats of Distinct HIV-1 Subtypes. The Open Virology Journal, 2007, 1, 26-32.	1.8	13
88	Immunopathogenesis of HIV Infection. , 2007, , 245-295.		2
89	Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. Antiviral Therapy, 2007, 12, 553-558.	1.0	6
90	Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood, 2006, 107, 4825-4833.	1.4	66

#	Article	IF	CITATIONS
91	Nef Alleles from Human Immunodeficiency Virus Type 1-InfectedLong-Term-Nonprogressor Hemophiliacs with or without Late Disease Progression Are Defective in Enhancing Virus Replication and CD4 Down-Regulation. Journal of Virology, 2006, 80, 10663-10674.	3.4	39
92	Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. Journal of Leukocyte Biology, 2006, 80, 1018-1030.	3.3	133
93	Pertussis Toxin B-Oligomer Suppresses IL-6 Induced HIV-1 and Chemokine Expression in Chronically Infected U1 Cells via Inhibition of Activator Protein 1. Journal of Immunology, 2006, 176, 999-1006.	0.8	23
94	Glycosyl Phosphatidylinositol-Anchored Proteins and HIV Infection. Letters in Drug Design and Discovery, 2006, 3, 598-604.	0.7	1
95	Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica, 2006, 91, 244-7.	3.5	8
96	Pertussis toxin B-oligomer dissociates T cell activation and HIV replication in CD4 T cells released from infected lymphoid tissue. Aids, 2005, 19, 1007-1014.	2.2	21
97	Dendritic Cells and Natural Killer Cells in the Pathogenesis of HIV Infection. Immunologic Research, 2005, 33, 001-022.	2.9	23
98	Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfusion Medicine, 2005, 15, 269-276.	1.1	35
99	Preparing for phase II/III HIV vaccine trials in Africa. Microbes and Infection, 2005, 7, 1436-44.	1.9	7
100	Bacterial Toxins: Potential Weapons Against HIV Infection. Current Pharmaceutical Design, 2005, 11, 2909-2926.	1.9	17
101	Immunomodulatory and Anti-Viral Activities of Pertussis Toxin and of Its Non-Toxic Derivatives. Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents, 2005, 4, 177-183.	0.4	0
102	Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. International Immunology, 2005, 17, 469-475.	4.0	22
103	Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Molecular Immunology, 2005, 42, 161-182.	2.2	106
104	Infection of CD4 + Primary T Cells and Cell Lines, Generation of Chronically Infected Cell Lines, and Induction of HIV Expression. Current Protocols in Immunology, 2005, 69, Unit 12.3.	3.6	4
105	<i>Coronaviridae</i> and SARS-associated Coronavirus Strain HSR1. Emerging Infectious Diseases, 2004, 10, 413-418.	4.3	127
106	Inhibition of HIVâ€I Replication in Monocyteâ€Derived Macrophages byMycobacterium tuberculosis. Journal of Infectious Diseases, 2004, 189, 624-633.	4.0	39
107	Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer. European Journal of Immunology, 2004, 34, 530-536.	2.9	16
108	Nitric Oxide Production in HIV-1 Infected Patients Receiving Intermittent Cycles of Interleukin-2 and Antiretrovirals. HIV Clinical Trials, 2004, 5, 146-151.	2.0	0

#	Article	IF	CITATIONS
109	T lymphocytes of HIV-positive individuals. Aids, 2004, 18, 327-328.	2.2	3
110	Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons. Antiviral Therapy, 2004, 9, 1003-1011.	1.0	77
111	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. International Journal of Cancer, 2003, 107, 958-961.	5.1	8
112	Double-edged effect of Vγ9/VÎ′2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. European Journal of Immunology, 2003, 33, 252-263.	2.9	23
113	CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and inγ δ T lymphocytes. European Journal of Immunology, 2003, 33, 3136-3145	2.9	15
114	Unplugging the T cell receptor. Nature Immunology, 2003, 4, 943-944.	14.5	2
115	Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV*1. Vaccine, 2003, 21, 2052-2064.	3.8	24
116	The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. Journal of Leukocyte Biology, 2003, 74, 750-756.	3.3	26
117	Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. Aids, 2003, 17, 2291-2298.	2.2	52
118	Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration. Aids, 2003, 17, 1621-1630.	2.2	1
119	Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. Aids, 2003, 17, 177-181.	2.2	31
120	Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte–derived macrophages. Blood, 2003, 102, 2334-2337.	1.4	55
121	Tumor Necrosis Factorα, Interleukin 2, and Soluble Interleukin 2 Receptor Levels in Human Immunodeficiency Virus Type 1-Infected Individuals Receiving Intermittent Cycles of Interleukin 2. AIDS Research and Human Retroviruses, 2002, 18, 491-499.	1.1	8
122	Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8862-8867.	7.1	61
123	Retroviral Interference on STAT Activation in Individuals Coinfected with Human T Cell Leukemia Virus Type 2 and HIV-1. Journal of Immunology, 2002, 169, 4443-4449.	0.8	19
124	Human T-cell leukemia virus type 2 induces survival and proliferation of CD34+ TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-γ and granulocyte macrophage–colony-stimulating factor. Blood, 2002, 99, 224-231.	1.4	20
125	INTERLEUKIN (IL)-4 INHIBITS PHORBOL-ESTER INDUCED HIV-1 EXPRESSION IN CHRONICALLY INFECTED U1 CELLS INDEPENDENTLY FROM THE AUTOCRINE EFFECT OF ENDOGENOUS TUMOUR NECROSIS FACTOR-1±, IL-11², AND IL-1 RECEPTOR ANTAGONIST. Cytokine, 2002, 17, 28-35.	, 3.2	10
126	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. Blood, 2002, 100, 1575-1578.	1.4	11

#	Article	IF	CITATIONS
127	The Cytokine Network in HIV Infection. Current Molecular Medicine, 2002, 2, 677-689.	1.3	44
128	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. Blood, 2002, 100, 1575-8.	1.4	3
129	IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. Journal of Leukocyte Biology, 2002, 72, 735-42.	3.3	14
130	Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4(+) T cells. Journal of Leukocyte Biology, 2002, 72, 913-20.	3.3	12
131	TUMOR NECROSIS FACTOR- $\hat{1}$ ± DRIVES HIV-1 REPLICATION IN U937 CELL CLONES AND UPREGULATES CXCR4. Cytokine, 2001, 13, 55-59.	3.2	18
132	Expression and Activation of a C-Terminal Truncated Isoform of STAT5 (STAT5Δ) Following Interleukin 2 Administration or AZT Monotherapy in HIV-Infected Individuals. Clinical Immunology, 2001, 99, 75-81.	3.2	11
133	Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Human Immunology, 2001, 62, 561-576.	2.4	55
134	Cytokine and Chemokine Based Control of HIV Infection and Replication. Current Pharmaceutical Design, 2001, 7, 993-1013.	1.9	36
135	Interleukin-6 and Glucocorticoids Synergistically Induce Human Immunodeficiency Virus Type-1 Expression in Chronically Infected U1 Cells by a Long Terminal Repeat Independent Post-Transcriptional Mechanism. Molecular Medicine, 2001, 7, 668-678.	4.4	21
136	Inhibition of R5X4 Dualtropic HIV-1 Primary Isolates by Single Chemokine Co-receptor Ligands. Virology, 2001, 280, 253-261.	2.4	19
137	The Binding Subunit of Pertussis Toxin Inhibits HIV Replication in Human Macrophages and Virus Expression in Chronically Infected Promonocytic U1 Cells. Journal of Immunology, 2001, 166, 1863-1870.	0.8	33
138	Efficacy of Lowâ€Ðose Intermittent Subcutaneous Interleukin (IL)–2 in Antiviral Drug–Experienced Human Immunodeficiency Virus–Infected Persons with Detectable Virus Load: A Controlled Study of 3 ILâ€2 Regimens with Antiviral Drug Therapy. Journal of Infectious Diseases, 2001, 183, 1476-1484.	4.0	48
139	Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. Journal of NeuroVirology, 2000, 6, 75-83.	2.1	64
140	Engagement of CD30 shapes the secretion of cytokines by human \hat{I}^3 $\hat{I}^{'}$ T cells. European Journal of Immunology, 2000, 30, 2172-2180.	2.9	22
141	HTLV-II down-regulates HIV-1 replication in IL-2–stimulated primary PBMC of coinfected individuals through expression of MIP-11̂±. Blood, 2000, 95, 2760-2769.	1.4	43
142	The B-Oligomer of Pertussis Toxin Inhibits Human Immunodeficiency Virus Type 1 Replication at Multiple Stages. Journal of Virology, 2000, 74, 8767-8770.	3.4	36
143	CCR2â€64IPolymorphism, Syncytiumâ€Inducing Human Immunodeficiency Virus Strains, and Disease Progression. Journal of Infectious Diseases, 2000, 182, 1579-1580.	4.0	10
144	Shorter Survival ofSDF1â€3′A/3′AHomozygotes Linked to CD4+T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2000, 182, 311-315.	4.0	70

#	Article	IF	CITATIONS
145	Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9162-9167.	7.1	41
146	Inhibition of CXCR4-Dependent HIV-1 Infection by Extracellular HIV-1 Tat. Biochemical and Biophysical Research Communications, 2000, 270, 992-996.	2.1	83
147	Ex Vivo Modulation of RANTES and sCD30 by Proinflammatory Stimuli in HIV-Seropositive and -Negative Individuals. Clinical Immunology, 2000, 97, 102-108.	3.2	4
148	Engagement of CD30 shapes the secretion of cytokines by human γ δT cells. European Journal of Immunology, 2000, 30, 2172.	2.9	18
149	Human Immunodeficiency Virus Replication Induces Monocyte Chemotactic Protein-1 in Human Macrophages and U937 Promonocytic Cells. Blood, 1999, 93, 1851-1857.	1.4	92
150	Human CD34+ Cells Express CXCR4 and Its Ligand Stromal Cell–Derived Factor-1. Implications for Infection by T-Cell Tropic Human Immunodeficiency Virus. Blood, 1999, 94, 62-73.	1.4	117
151	Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection. Blood, 1999, 94, 4202-4209.	1.4	77
152	Role of Peripheral Blood Mononuclear Cell Subsets of Seronegative Donors in HIV Replication: Suppression by CD8+ and CD16+ Cells and Enhancement by CD14+ Monocytes. AIDS Research and Human Retroviruses, 1999, 15, 489-491.	1.1	6
153	Laureate ESCI award for excellence in clinical science 1999 Cytokines and the human immunodeficiency virus: from bench to bedside. European Journal of Clinical Investigation, 1999, 29, 723-732.	3.4	36
154	Defective nef Alleles in a Cohort of Hemophiliacs with Progressing and Nonprogressing HIV-1 Infection. Virology, 1999, 259, 349-368.	2.4	53
155	Dual role of TNF-α in NK / LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. European Journal of Immunology, 1999, 29, 3654-3662.	2.9	14
156	Dual role of TNF-α in NK / LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. European Journal of Immunology, 1999, 29, 3654-3662.	2.9	1
157	Envelope-Dependent Restriction of Human Immunodeficiency Virus Type 1 Spreading in CD4 ⁺ T Lymphocytes: R5 but Not X4 Viruses Replicate in the Absence of T-Cell Receptor Restimulation. Journal of Virology, 1999, 73, 7515-7523.	3.4	52
158	Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection. Blood, 1999, 94, 4202-4209.	1.4	31
159	CCR2 Polymorphism and HIV Disease. Nature Medicine, 1998, 4, 252-253.	30.7	63
160	Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes. Journal of Experimental Medicine, 1998, 187, 439-444.	8.5	230
161	Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. Aids, 1998, 12, 1327-1332.	2.2	226
162	Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line. Blood, 1998, 91, 258-265.	1.4	205

#	Article	IF	CITATIONS
163	1,25-Dihydroxyvitamin D3 Upregulates Functional CXCR4 Human Immunodeficiency Virus Type 1 Coreceptors in U937 Minus Clones: NF-κB-Independent Enhancement of Viral Replication. Journal of Virology, 1998, 72, 8380-8383.	3.4	27
164	Double doors and gatekeepers: HIV co-receptors and chemokines. Drug News and Perspectives, 1998, 11, 620.	1.5	1
165	Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line. Blood, 1998, 91, 258-265.	1.4	12
166	MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Journal of Leukocyte Biology, 1997, 62, 30-33.	3.3	60
167	Role of proinflammatory cytokines and β-chemokines in controlling HIV replication. Journal of Leukocyte Biology, 1997, 62, 34-40.	3.3	67
168	EXPRESSION OF MONOCYTE CHEMOTACTIC PROTEIN-3 IN HUMAN MONOCYTES EXPOSED TO THE MYCOBACTERIAL CELL WALL COMPONENT LIPOARABINOMANNAN. Cytokine, 1997, 9, 992-998.	3.2	54
169	Transmission of HIV-1 and HCV by head-butting. Lancet, The, 1997, 350, 1370.	13.7	12
170	Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/Δccr5) genotype is neither essential nor sufficient for protection against disease progression. European Journal of Immunology, 1997, 27, 3223-3227.	2.9	39
171	Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound tumour necrosis factor (TNF)-α receptor type 1 in a promonocytic cell line. Aids, 1996, 10, 835-842.	2.2	21
172	Selective Elevation of Monocyte Chemotactic Protein-1 in the Cerebrospinal Fluid of AIDS Patients with Cytomegalovirus Encephalitis. Journal of Infectious Diseases, 1996, 174, 1098-1100.	4.0	101
173	Cytokines and Soluble Receptor Changes in the Transition from Primary to Early Chronic HIV Type 1 Infection. AIDS Research and Human Retroviruses, 1996, 12, 325-331.	1.1	33
174	Cytokine Cascades in HIV Infection. , 1996, , 285-301.		5
175	Cytokines in the acquired immunodeficiency syndrome and other infectious diseases. International Journal of Clinical and Laboratory Research, 1995, 25, 128-134.	1.0	17
176	Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist Journal of Experimental Medicine, 1995, 182, 623-628.	8.5	112
177	IL-10 Synergizes with Multiple Cytokines in Enhancing HIV Production in Cells of Monocytic Lineage. Journal of Acquired Immune Deficiency Syndromes, 1995, 9, 442???449.	0.3	51
178	Interleukin 10 Blocks HIV Replication in Macrophages by Inhibiting the Autocrine Loop of Tumor Necrosis Factor α and Interleukin 6 Induction of Virus. AIDS Research and Human Retroviruses, 1994, 10, 1199-1206.	1.1	151
179	Elevated Levels of Tumor Necrosis Factor-α in Zairian Neonate Plasmas: Implications for Perinatal Infection with the Human Immunodeficiency Virus. Journal of Infectious Diseases, 1994, 169, 975-980.	4.0	20
180	A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells Journal of Experimental Medicine, 1994, 180, 1445-1456.	8.5	99

#	Article	IF	CITATIONS
181	NF- \hat{I}° B-Dependent and -Independent Pathways of HIV Activation in a Chronically Infected T Cell Line. Virology, 1994, 202, 684-694.	2.4	72
182	Ultraviolet irradiation and cytokines as regulators of HIV latency and expression. Chemico-Biological Interactions, 1994, 91, 101-109.	4.0	17
183	Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Research, 1994, 24, 221-233.	4.1	73
184	Regulation of HIV expression by viral genes and cytokines. Journal of Leukocyte Biology, 1994, 56, 328-334.	3.3	40
185	Expression and modulation of a mononuclear phagocyte differentiation antigen (PAM-1) during in vitro maturation of peripheral blood monocytes. International Journal of Clinical and Laboratory Research, 1993, 23, 83-87.	1.0	6
186	The Chronically Infected Promonocytic Cell Line U1: A Model of HIV Expression Regulated by Cytokines. ImmunoMethods, 1993, 3, 50-55.	0.8	11
187	Cytokine modulation of HIV expression. Seminars in Immunology, 1993, 5, 165-173.	5.6	146
188	Glucocorticoids Synergize with Tumor Necrosis Factor α in the Induction of HIV Expression from a Chronically Infected Promonocytic Cell Line. AIDS Research and Human Retroviruses, 1993, 9, 547-551.	1.1	20
189	A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2537-2541.	7.1	41
190	Infection of CD 4 + Primary Cell Lines and Induction of HIV. Current Protocols in Immunology, 1993, 5, 12.3.1.	3.6	1
191	Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells Journal of Experimental Medicine, 1992, 176, 739-750.	8.5	148
192	The Role of Monocyte/Macrophages and Cytokines in the Pathogenesis of HIV Infection. Pathobiology, 1992, 60, 246-251.	3.8	70
193	Retinoic acid mimics transforming growth factor beta in the regulation of human immunodeficiency virus expression in monocytic cells Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2689-2693.	7.1	87
194	The Effect of Cytokines and Pharmacologic Agents on Chronic HIV Infection. AIDS Research and Human Retroviruses, 1992, 8, 191-197.	1.1	247
195	Dissociation between syncytia formation and HIV spreading. Suppression of syncytia formation does not necessarily reflect inhibition of HIV infection. European Journal of Immunology, 1991, 21, 1771-1774.	2.9	31
196	Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1 Journal of Experimental Medicine, 1991, 173, 1-5.	8.5	126
197	Defective chemotaxis of human alveolar macrophages. Clinical Immunology and Immunopathology, 1988, 47, 282-288.	2.0	4

Multiple Roles of Cytokines in HIV Infection, Replication, and Therapy. , 0, , 293-311.

1